Daniel Lebovic

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand et al. · Journal of Clinical Oncology · 2016 · 1K citations · Full text

Medicine, Hematology, Oncology +17

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens G. Lohr, Petar Stojanov, Scott L. Carter et al. · Cancer Cell · 2014 · 1K citations · Full text

Medicine, Hematology, Molecular Genetics +16

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith et al. · Blood · 2012 · 434 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor et al. · Clinical Cancer Research · 2015 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Hongxiu Li, Mark Kaminski, Yifeng Li et al. · Blood · 2014 · 182 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14